 OncLive | Prognostic Factors for Progression of Neuroendocrine Tumors Identified in ... OncLive The placebo-controlled phase III RADIANT-2 trial showed that the addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progressionfree survival (PFS) in patients with advanced neuroendocrine tumors (NETs). |
